INS and type 2 diabetes mellitus: Our group showed that the insulin sensitizer pioglitazone improved whole-body insulin sensitivity and insulin-mediated myocardial glucose utilisation together with an improvement in myocardial diastolic function in patients with well-controlled T2DM [29].